1. Scrip
  2. >>R&D

FibroGen Rocked By Second Pivotal Pamrevlumab Failure – This Time In IPF

Stock Down By 79.9%

 
• By Ayisha Sharma

Months after a disappointment in Duchenne muscular dystrophy, the US firm’s pamrevlumab has missed the mark in a pivotal idiopathic pulmonary fibrosis trial, boding poorly for other trials and forcing the firm to enter cost-cutting mode.  

hand throwing ball of paper into wastebasket
FibroGen Is Scrapping Another Phase III Trial In IPF After The Failure • Source: Shutterstock

FibroGen, Inc.’s monoclonal antibody candidate pamrevlumab has disappointed in the Phase III ZEPHYRUS-1 trial in idiopathic pulmonary fibrosis (IPF), rendering the drug’s future prospects even more uncertain and triggering cost-saving measures.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

More from R&D